Literature DB >> 10381131

Cloning genes responsive to a hepatocarcinogenic peroxisome proliferator chemical reveals novel targets of regulation.

J C Corton1, E S Moreno, A Merritt, C Bocos, R C Cattley.   

Abstract

To better understand the molecular basis of the hepatocyte proliferation and induction of hepatocellular adenomas by exposure to peroxisome proliferator chemicals (PPC), a systematic search for genes modulated by a PPC (WY-14643) in rat liver was carried out using the differential display technique. The fragments fell into two classes based on the time of initial and maximal induction by WY-14643. The class I genes (clones 5 and 30) were induced 3 h after a gavage exposure to WY-14643 with maximal expression at 24 h. The class II genes (clones 13 and 16) were induced after 24 h with maximal expression at 78 weeks. Expression of the class II genes was also increased after other treatments that cause cell proliferation. Clone 30 was identified as CYP4A2, previously shown to be regulated by PPC. Clone 13 was homologous to the mouse protein H gene, a component of the heterogeneous nuclear ribonucleoprotein particle important in mRNA splicing. Clone 16 was identified as cyclophilin-A, the receptor for the immunosuppressant drug cyclosporin A. The sequence of clone 5 was unique. These data demonstrate that WY-14643 increases the levels of a number of novel genes that are coordinately regulated with increases in chronic cell proliferation and fatty acid metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10381131     DOI: 10.1016/s0304-3835(98)00241-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Current implications of cyclophilins in human cancers.

Authors:  Jinhwa Lee; Sung Soo Kim
Journal:  J Exp Clin Cancer Res       Date:  2010-07-19

2.  Peroxisome proliferator-activated receptorα agonists differentially regulate inhibitor of DNA binding expression in rodents and human cells.

Authors:  María Del Carmen González; J Christopher Corton; Nuria Acero; Dolores Muñoz-Mingarro; Yolanda Quirós; Juan José Alvarez-Millán; Emilio Herrera; Carlos Bocos
Journal:  PPAR Res       Date:  2012-06-04       Impact factor: 4.964

3.  3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy.

Authors:  Makoto Saito; Takashi Takano; Tomohiro Nishimura; Michinori Kohara; Kyoko Tsukiyama-Kohara
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

4.  Expression and prognostic relevance of cyclophilin A and matrix metalloproteinase 9 in esophageal squamous cell carcinoma.

Authors:  Yi Li; Hui Guo; Danfeng Dong; Huili Wu; Enxiao Li
Journal:  Diagn Pathol       Date:  2013-12-18       Impact factor: 2.644

5.  Co-expression network analysis of gene expression profiles of HER2+ breast cancer-associated brain metastasis.

Authors:  Feng Yuan; Wei Wang; Hongtao Cheng
Journal:  Oncol Lett       Date:  2018-10-10       Impact factor: 2.967

6.  Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9.

Authors:  Zhe Qian; Xiaoting Zhao; Mei Jiang; Wenyun Jia; Chunyan Zhang; Yue Wang; Baolan Li; Wentao Yue
Journal:  BMC Cancer       Date:  2012-10-02       Impact factor: 4.430

Review 7.  Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma.

Authors:  Jinhwa Lee
Journal:  Korean J Physiol Pharmacol       Date:  2013-10-17       Impact factor: 2.016

8.  Cyclophilin A promotes non-small cell lung cancer metastasis via p38 MAPK.

Authors:  Yinan Guo; Mei Jiang; Xiaoting Zhao; Meng Gu; Ziyu Wang; Shaofa Xu; Wentao Yue
Journal:  Thorac Cancer       Date:  2017-11-07       Impact factor: 3.500

Review 9.  The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.

Authors:  Lifang Liang; Rongxiao Lin; Ying Xie; Huaqing Lin; Fangyuan Shao; Wen Rui; Hongyuan Chen
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.